SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is generating buzz among traders who are attracted to its active developer engagement and the community's push to build organic momentum, despite the project's early stage and lack of an official chart. Investors are actively discussing the potential for a significant breakout, emphasizing the need for sustained volume and broader social media promotion to move the token toward mainstream visibility.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MullenArmy (MULN CRYPTO) is currently trending as members debate its viability, with many in the community labeling it a pump-and-dump scheme or comparing it to the Mullen Automotive stock decline. While some users attempt to rally interest through community-led narratives and crypto-market speculation, others are actively warning investors to exit to avoid potential financial losses.

iShares Inc. - iShares MSCI Mexico ETF

iShares MSCI Mexico ETF

Investors are actively debating the long-term viability of Mexico as a manufacturing hub, with some noting its strategic importance in nearshoring supply chains while others warn of socio-economic decay and political risks. The community is focused on the impact of trade tariffs and US-Mexico relations on the performance of $EWW.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

The XRP community remains deeply divided, with some investors accumulating tokens in anticipation of regulatory clarity and institutional adoption, while others express frustration over long-term price stagnation and perceived lack of progress. Debates are currently fueled by speculation surrounding the Clarity Act and the expansion of Ripple's payment infrastructure, leading to a polarized environment between optimistic long-term holders and disillusioned skeptics.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. is trending as investors monitor its development as a rare earth metals processor amid increasing urgency for U.S.-aligned supply chains. The community is actively debating the stock's long-term potential in the defense sector, with heavy discussions focused on the company's advisory board appointments, defense-related contracts, and the risks versus rewards associated with future production timelines.

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals is trending following an Endpoints News report alleging that FDA Commissioner Marty Makary attempted to force a rejection of the company's hereditary angioedema (HAE) drug application, an effort that was reportedly blocked by internal FDA scientists. Investors are actively discussing the stock's resilience, as the company maintains its path toward potential approval for the first oral on-demand treatment for HAE while bulls view the resulting price volatility as a favorable opportunity to increase positions.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently a focal point for investors due to clinical progress with its ITK inhibitor, soquelitinib, which has generated buzz for its potential to deliver durable, disease-modifying outcomes in atopic dermatitis and oncology. Community sentiment remains highly polarized, with intense debate between bulls anticipating a strategic buyout or short squeeze and skeptics emphasizing the inherent risks of a clinical-stage biotech and the potential for share dilution.

Invesco Exchange-Traded Fund Trust II - Invesco Solar ETF

Invesco Solar ETF

Invesco Solar ETF is navigating heightened market volatility as investors weigh the impact of shifting political landscapes and policy rhetoric on long-term renewable energy demand. The community is actively debating the sector's resilience, with many pointing to the structural necessity of solar to support the power-intensive growth of AI and data center infrastructure despite short-term regulatory headwinds.

ETF Series Solutions - ESS U.S.Global Jets ETF

US Global Jets ETF

Airline stocks are facing renewed volatility as the sector grapples with potential operational disruptions, fuel cost pressures, and broader economic uncertainty. The community is actively debating the sustainability of travel demand and debating whether the recent price action offers a contrarian value opportunity or a warning of deeper industry headwinds.

Investment Managers Series Trust II - Tradr 1.5X Short NVDA Daily ETF

Tradr 1.5X Short NVDA Daily ETF

The $NVDS ETF is seeing intense activity as traders debate whether Nvidias rally is sustainable or if a major pullback is imminent. The community is heavily focused on using this inverse instrument as a tactical hedge or aggressive short, with active discussions weighing technical support levels and the risks of betting against such a volatile market leader.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

India’s Balaji Amines stops operations at some plants on feedstock shortage

MUMBAI (ICIS)--India’s Balaji Amines has stopped operations at some of its plants due to shortage of feedstock ammonia, it said in a statement. The company “is currently experiencing significant...

Most Traded NSE Stocks in 2026: High Volume Picks

NSE stocks with high volume include Balaji Amines, Madras Fertilizers, and Jindal Photo. The list explains volume trends and the latest market insights in India.

Indian authorities have reportedly accused Balaji Amines&nbsp;of manufacturing pharmaceutical-grade propylene glycol (PG) without a valid drug license, after a batch of its product was found to be substandard.The probe began when a 2023 batch failed quality checks due to excess water content. However, no contamination, such as toxic ethylene glycol or diethylene glycol, was detected, according to a report by Reuters.However, test reports have confirmed that Balaji’s PG was free of contaminants.What Is Propylene Glycol Used For?Propylene glycol is a solvent used in food, cosmetics, and medicines. However, it has been under scrutiny following contamination incidents in Indian-made cough syrups linked to child deaths. Earlier this month, the World Health Organization (WHO) had raised serious concerns about regulatory shortcomings that enabled toxic substitutes to enter medicines.The company stated that it only produces technical and food-grade PG and has not sold any material “intended for pharmaceutical applications” since beginning production in 2022.Balaji said some non-pharma customers had requested tests based on U.S. and Indian pharmacopoeia standards (USP/IP), which is why such labels appeared on certain batches. The firm has already applied for a licence to manufacture pharma-grade PG and is awaiting approval, the report added.In March, the Central Drugs Standard Control Organization (CDSCO) inspected the company’s facility and sealed some samples for further verification. Balaji confirmed the visit but said there was no ongoing investigation at present.Stock Watch<a href="https://stocktwits.com/symbol/BALAMINES.NSE">Balaji Amines’ stock</a> closed 1.25% lower at ₹1,349 on Tuesday.Year-to-date, the shares have declined nearly 25%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Financial market volatility on digital interface with fluctuating trading data real-time stock market analysis and investment trends. (Stock picture/Getty Images)

Balaji Amines Under Scrutiny Over Unlicensed Propylene Glycol Production: Report 

The probe began when a 2023 batch failed quality checks due to excess water content. The firm has denied selling the chemical for pharma use.

Equity

Several Indian-listed chemical companies have been highlighted as potential beneficiaries of the government’s July 2025 policy focus on boosting the chemical sector.SEBI-registered analyst&nbsp;<a href="https://stocktwits.com/Srireddy2075">Srinivasa Reddy</a> cited the NITI Aayog report titled “Chemical Industry: Powering India’s Participation in Global Value Chains” to identify stocks aligned with the report’s strategic interventions, policy reforms, and market-linked opportunities.According to Reddy, the report outlines opportunities in five key areas: specialty chemical exports, petrochemical backward integration, battery and electronic chemicals, infrastructure-led chemical hubs, and technology-dependent products.&nbsp;<stembedurl>https://stocktwits.com/Srireddy2075/message/620285403</stembedurl>Reddy listed the following companies and their alignment with the report:SRF&nbsp;Operating in specialty chemicals, fluorochemicals, and packaging films,&nbsp;<a href="https://stocktwits.com/symbol/SRF.NSE">SRF</a> is focused on agrochemicals and refrigerants with export potential.&nbsp;Reddy said it is likely to benefit from R&amp;D incentives and technology upgrades, and it already caters to global clients.Aarti Industries&nbsp;With a presence in agrochemicals, dyes, and pharma intermediates, Reddy noted&nbsp;<a href="https://stocktwits.com/symbol/AARTIIND.NSE">Aarti Industries</a> as one of India’s largest specialty chemical exporters.&nbsp;He added that the company is aligned with operational subsidies and technology partnership initiatives.Navin Fluorine&nbsp;Specializing in fluorine-based chemicals, Reddy said&nbsp;<a href="https://stocktwits.com/symbol/NAVINFLUOR.NSE">Navin Fluorine</a> fits into the sunrise sector and R&amp;D-led innovation focus due to its high-value, low-volume exports.Gujarat FluorochemicalsInvolved in specialty fluoropolymers and refrigerants, Reddy noted&nbsp;<a href="https://stocktwits.com/symbol/FLUOROCHEM.NSE">Gujarat Fluorochemicals’</a> alignment with the report’s incentives for import substitution and exports in sunrise sectors.Deepak Nitrite / Deepak Fertilisers&nbsp;Reddy observed&nbsp;<a href="https://stocktwits.com/symbol/DEEPAKNTR.NSE">Deepak Nitrite</a> is the only domestic manufacturer of phenol, one of the products flagged in the report for import substitution, along with acetic acid.Grasim (Aditya Birla Chemicals)&nbsp;Operating in epoxy resins, caustic soda, and other industrial chemicals, Reddy stated that&nbsp;<a href="https://stocktwits.com/symbol/GRASIM.NSE">Grasim</a> stands to gain from domestic manufacturing and cluster-based infrastructure investments.Balaji Amines&nbsp;Engaged in amines, derivatives, and pharma intermediates,&nbsp;<a href="https://stocktwits.com/symbol/BALAMINES.NSE">Balaji Amines</a> fits into the import substitution and technology competitiveness frameworks outlined in the report, according to Reddy.Clean Science &amp; Technology&nbsp;Reddy highlighted&nbsp;<a href="https://stocktwits.com/symbol/CLEAN.NSE">Clean Science &amp; Technology’s</a> alignment with the green chemistry agenda, low carbon profile, and CBAM (Carbon Border Adjustment Mechanism) readiness under the R&amp;D intervention.Laxmi Organic Industries&nbsp;Producing acetyl and specialty intermediates, Reddy pointed out that&nbsp;<a href="https://stocktwits.com/symbol/LXCHEM.NSE">Laxmi Organic Industries'</a> expansion into fluorochemicals and acetic acid positions it well for operational and strategic support.Tata Chemicals&nbsp;With exposure to soda ash, specialty nutrition, and battery materials,&nbsp;<a href="https://stocktwits.com/symbol/CLEAN.NSE">Tata Chemicals</a> is recognized for its strong R&amp;D backing and its role in emerging sectors, particularly lithium battery materials.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Chemical Policy Boost: SEBI RA Highlights Tata Chemicals, SRF, Deepak Nitrite, Grasim, Among Others, As Reform Winners

The analyst highlighted a list of Indian chemical companies that align with strategic opportunities outlined in the July 2025 NITI Aayog report. 

Shares of Balaji Amines rose nearly 3% on Thursday after the company said it had received consent to operate its Isopropylamine (MIPA/DIPA) manufacturing facility.&nbsp;Trial runs are expected to begin shortly, with commercial production to follow.The stock has rallied nearly 20% in the last one month.&nbsp;SEBI-registered analyst&nbsp;<a href="https://stocktwits.com/Rajneesh_Sharma_Official">Rajneesh Sharma</a> said that the recent move of&nbsp;<a href="https://stocktwits.com/symbol/BALAMINES.NSE">Balaji Amines shares</a> to ₹1,680 aligns with a historical trendline setup observed in prior cycles, including 2014 and 2020.&nbsp;<stembedurl>https://stocktwits.com/Rajneesh_Sharma_Official/message/618908045</stembedurl>The analyst noted that the long-term logarithmic trendline continues to act as a strong support, with volume patterns suggesting the breakout is still in its early phase.Sharma pointed to Balaji Amines’ balance sheet improvements over the past five years, citing a drop in borrowings from ₹260 crore to ₹11 crore.He also noted a rise in reserves from ₹652 crore to ₹1,839 crore, enabled by over ₹1,100 crore in capex, largely funded through internal accruals.Key business drivers being tracked include the ramp-up of DME, DMC, and NBPT capacities, as well as backward integration through BSCL to reduce raw material costs.&nbsp;The analyst added that while methanol prices pose a near-term risk to margins, the broader structural thesis remains intact.A target range of ₹2,800–₹3,900 over 12–24 months has been maintained, contingent on volume confirmation and a continuation of the current technical setup.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:985/138;" src="https://news.stocktwits-cdn.com/balaji_amines_ss_jpg_675d0f5ebe.webp" alt="balaji amines ss.jpg" width="985" height="138"><figcaption>BALAMINES sentiment and message volume as of June 26, 12.30 pm IST. Source: Stocktwits.</figcaption></figure>The stock has declined 4.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Balaji Amines Shares Gain On New Plant Approval: SEBI RA Rajneesh Sharma Sees Potential For Over 100% Returns Over 1-2 Years

The stock’s recent price move has mirrored past cycles, with technical and balance sheet trends reinforcing the ongoing breakout. 

Balaji Amines is retesting a key long-term support zone as the company nears completion of a ₹1,100 crore capex cycle, SEBI-registered analyst&nbsp;<a href="https://stocktwits.com/Rajneesh_Sharma_Official">Rajneesh Sharma</a> said.<stembedurl>https://stocktwits.com/Rajneesh_Sharma_Official/message/616603624</stembedurl>At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/BALAMINES.NSE">Balaji Amines shares</a> were trading at ₹1,472.50, down 0.86% or ₹12.70 on the day.The stock is currently testing a logarithmic trendline that has historically preceded major rallies: in 2014, the stock rallied about 10 times over 3.5 years after a similar test, and in 2020, it surged sixfold within 18 months.&nbsp;Balaji Amines is&nbsp;already back at this critical level&nbsp;this year, supported by strong financials and ongoing capital expenditure.The company’s balance sheet shows significant progress: borrowings have been reduced from ₹260 crore to ₹11 crore, while reserves nearly tripled to ₹1,839 crore.&nbsp;Capex has been funded mainly through internal accruals, avoiding dilution or increased leverage.Operationally, Balaji Amines is expanding production capacity with an expected volume of around 287,000 MT and projected FY26 revenue of ₹3,900–₹4,200 crore.&nbsp;The estimated profit after tax is ₹430 crore, with an EPS forecast of ₹133.&nbsp;The analyst suggests a potential valuation uplift to nearly ₹4,000 per share based on a 30x PE multiple.Key business drivers include leadership in the 88,000 TPA methylamines segment, growth in battery chemicals aligned with the EV ecosystem, and a ₹750 crore import substitution project through its BSCL subsidiary.&nbsp;Energy costs are expected to decrease with a solar plant rollout aiming for 20 MW capacity.Rajneesh Sharma recommends an entry zone between ₹1,400 and ₹1,500, with a 12–24 month target of ₹2,800 to ₹3,900.&nbsp;He notes that, depending on successful execution and market conditions, this could be the first phase of a longer-term re-rating cycle.On Stocktwits, retail sentiment was ‘neutral’ amid ‘high’ message volume.The stock has declined 18.3% so far in 2025.

In this photo illustration, graph on a trader's computer screen, representing the concept of trading financial instruments. (Photo Illustration by Roberto Machado Noa/LightRocket via Getty Images)

Balaji Amines Retests Key Long-Term Support As ₹1,100 Cr Capex Cycle Nears Completion: SEBI RA Rajneesh Sharma

The company’s expansion in high-margin chemical products and new capacity projects supports its optimistic revenue and profit growth outlook.

Breakdown Stocks: How to trade Astral, Balaji Amines & IDFC First Bank on Monday?

Indian markets closed lower on Thursday amid weak global cues. Sectorally, power and PSU stocks gained, while metals and autos declined. Analysts highlight crucial support levels for IDFC First Bank, Balaji Amines, and Astral.

Balaji Amines Ltd. engages in the manufacture and sale of specialty chemicals, aliphatic amines, and derivatives. It operates through the following segments: Amines and Specialty Chemicals, Hotel, and CFL Lamps. The company was founded on October 27, 1988 and is headquartered in Hyderabad, India.

BALAMINES.NSE
Balaji Amines Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest BALAMINES.NSE News

BALAMINES.NSEBalaji Amines Ltd.